Landanger Camus benefits from AMP acquisition
This article was originally published in Clinica
Revenues at French orthopaedic implant manufacturer Landanger Camus increased to Fr 441 million ($88 million) in fiscal 1995, up 7.3% compared with last year. The company says without the acquisition of ankle prosthesis producer AMP earlier this year (see Clinica No 652, p 1), turnover would have risen only 3.8%. Foreign sales accounted for around 27% of sales for the year.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.